Name: Anti-Human PD1 (Camrelizumab Biosimilar)
Brand: InnoCyto
SKU: 501202
Price: 590 USD
Availability: InStock

Shop Now Contact

Anti-Human PD1 (Camrelizumab Biosimilar)

InnoCyto Product Image

Cat #	Size	Price
501201	1 mg	$190
501202	5 mg	$590
501203	20 mg	$1390

Bulk/Custom

Product Details

Clone	Camrelizumab
Application	Flow cytometry, animal model study
Host Species	Mammalian cells
Reactivity	Human
Format	Liquid
Product Description	Anti-Human PD-1 (Camrelizumab Biosimilar)
Isotype	Human IgG4
Regulatory Status	RUO
Clonality	Recombinant
Immunogen	Human PD1
Species specificity	Human
Purity	>95% by reducing SDS-PAGE
Grade	In vivo
Storage Conditions	4ºC
Maximal Shelf Life	12 months
Synonyms	CD279
Target Name	PD1, PD-1, PDCD1, CD279, SLEB2
Antibody Type	Recombinant
Research Areas	Immune Checkpoints, Activated T cells, Cancer Immunology, Tregs, Tfh cells, Activated B cells
See All Formats	Clone Camrelizumab

Background Information

Camrelizumab is a humanized monoclonal antibody that belongs to the immunoglobulin G4 (IgG4) subclass and is engineered to specifically bind to the programmed death-1 (PD-1) receptor on immune cells. Structurally, it is a full-length antibody composed of two identical heavy chains and two identical light chains, linked by disulfide bonds to form the characteristic Y-shaped structure of immunoglobulins. The molecule has a molecular mass of approximately 146 kilodaltons (kDa) and is produced using mammalian cell expression systems, such as Chinese Hamster Ovary (CHO) cells, to ensure proper glycosylation, folding, and structural stability.

The variable domains of the heavy (VH) and light (VL) chains contain complementarity-determining regions (CDRs) that form the antigen-binding site responsible for recognizing the PD-1 receptor with high affinity and specificity. This interaction is primarily stabilized by hydrogen bonding and hydrophobic contacts between the CDR loops of Camrelizumab and amino acid residues located on the extracellular domain of PD-1. This binding prevents PD-1 from interacting with its natural ligands, PD-L1 and PD-L2, which normally mediate inhibitory immune signaling. By blocking this receptor–ligand pathway, Camrelizumab modulates the signaling cascade that downregulates T-cell activation in immunological model systems.

Camrelizumab’s constant region, derived from the IgG4 isotype, confers specific biophysical properties. The IgG4 Fc region has been engineered with a stabilizing S228P substitution to prevent half-antibody formation, enhancing molecular integrity. Compared to IgG1 antibodies, the IgG4 subtype exhibits minimal effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), ensuring that the molecule primarily functions through receptor blockade rather than immune cell recruitment. The Fc domain also interacts with neonatal Fc receptors (FcRn) to extend the half-life of the antibody through recycling processes. Overall, Camrelizumab exemplifies a rationally designed IgG4 monoclonal antibody optimized for structural stability, receptor selectivity, and precise modulation of PD-1–mediated immune pathways.

Frequently Asked Questions

What are InnoCyto Biosimilar products?

InnoCyto biosimilars are research-grade recombinant antibodies or proteins engineered to closely replicate the sequence, structure, and target-binding activity of approved or well-characterized therapeutic antibodies (e.g., checkpoint inhibitors, anti-cytokine biologics). They are intended for research use to study the mechanism of action, efficacy, and combination potential of these therapeutic classes without the cost or access restrictions of clinical-grade material.

How similar are these biosimilars to the original therapeutic antibody?

Each biosimilar is produced using the published or inferred variable region sequence of the reference therapeutic and is expressed recombinantly to match the parent antibody's target specificity, isotype, and general binding profile. While designed for high functional similarity, InnoCyto biosimilars are for research use only and are not clinically validated equivalents of the approved drug product.

Are these antibodies suitable for in vivo studies?

Yes. InnoCyto biosimilars are manufactured with the same low-endotoxin, azide-free, carrier-free standards used across our in vivo product lines, making them suitable for animal efficacy, combination, and mechanism-of-action studies. Product pages indicate whether a given biosimilar is validated for in vivo use, in vitro use, or both.

What is the difference between a biosimilar and a recombinant "research antibody" targeting the same protein?

A biosimilar is specifically designed to mimic a known, named therapeutic antibody (matching its clinical target epitope and mechanism), whereas a general recombinant research antibody may target the same protein but bind a different epitope or lack the same functional properties. Biosimilars are the right choice when your study is benchmarking against, or modeling the action of, an approved or clinically studied biologic.

What quality and purity standards do biosimilar antibodies meet?

All biosimilars undergo the same rigorous QC pipeline as our other antibody lines: ≥95% purity by SDS-PAGE/SEC-HPLC, low-endotoxin testing via LAL assay, and binding/functional validation against the intended target. Certificates of Analysis (CoA) are provided per lot with full specifications.

Which therapeutic targets and mechanisms are covered in the Biosimilar line?

The line spans major immuno-oncology and immunology targets, including immune checkpoint pathways (e.g., PD-1/PD-L1, CTLA-4), cytokine and cytokine-receptor blockers, and other clinically relevant mechanisms. See each product page for the specific reference therapeutic and mechanism of action represented.

Have a product or application question? Consult our FAQs or contact us.

Search Tips